A good update. We now know where all current programs are up to, whether later than expected or not.
I particularly liked the following:
"ResAppDx-EU willprovide clinicians with the first rapid and accurate test for the most commonly-seen acuterespiratory diseases. It has the potential to have far-reaching benefits for the healthcare systemand we are working with a German private hospital network this European winter to quantifythese benefits.”
Quantification of benefits is imo very important to enable a reasonable commercial value to be placed on the app in its current status and abilities
